Lumos Pharma
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 33
- Market Cap
- $31.6M
- Website
- http://www.lumos-pharma.com
A Long-Term Safety Trial of LUM-201 in Children With Idiopathic Growth Hormone Deficiency Who Have Previously Completed a LUM-201 Clinical Trial (OraGrowtH211)
Phase 2
- Conditions
- Growth Hormone Deficiency
- Interventions
- Drug: LUM-201
- First Posted Date
- 2023-04-03
- Last Posted Date
- 2024-02-15
- Lead Sponsor
- Lumos Pharma
- Target Recruit Count
- 60
- Registration Number
- NCT05796440
- Locations
- 🇦🇺
Canberra Hospital, Garran, Australian Capital Territory, Australia
🇺🇸University of Iowa, Iowa City, Iowa, United States
🇺🇸Seattle Children's Hospital, Seattle, Washington, United States
Phase 2 Study of LUM-201 in Children Who Have Previously Completed the LUM-201-01 Trial (OraGrowtH213)
Phase 2
Active, not recruiting
- Conditions
- Growth Hormone Deficiency
- Interventions
- Drug: LUM-201
- First Posted Date
- 2022-02-22
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Lumos Pharma
- Target Recruit Count
- 18
- Registration Number
- NCT05250063
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸The Children's Mercy Hospital, Kansas City, Missouri, United States
🇺🇸Rady Children's Hospital, San Diego, California, United States
PK and PD Study of LUM-201 in Children With Idiopathic Growth Hormone Deficiency: (OraGrowtH212)
Phase 2
Active, not recruiting
- Conditions
- Growth Hormone Deficiency
- Interventions
- Drug: LUM-201
- First Posted Date
- 2021-03-19
- Last Posted Date
- 2023-10-04
- Lead Sponsor
- Lumos Pharma
- Target Recruit Count
- 24
- Registration Number
- NCT04806854
- Locations
- 🇨🇱
Institute of Maternal and Child Research, University of Chile, Santiago, Chile
Phase 2 Study of LUM-201 in Children With Growth Hormone Deficiency (OraGrowtH210 Trial)
Phase 2
Completed
- Conditions
- Growth Hormone Deficiency
- Interventions
- Drug: LUM-201Drug: rhGH Norditropin® pen (34 µg/kg)
- First Posted Date
- 2020-11-04
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Lumos Pharma
- Target Recruit Count
- 82
- Registration Number
- NCT04614337
- Locations
- 🇺🇸
The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Atlanta Diabetes Associates, Atlanta, Georgia, United States
🇺🇸Children's National Hospital, Washington, District of Columbia, United States
© Copyright 2025. All Rights Reserved by MedPath